Related Experiment Videos
Smad4 as a transcription corepressor for estrogen receptor alpha
Liyu Wu1, Yalei Wu, Bill Gathings
1Department of Pathology, University of Alabama at Birmingham, School of Medicine, Birmingham, Alabama 35294, USA.
Abstract:
Antiestrogen compounds exhibit a variety of different effects in different tissues and are widely used for the treatment of osteoporosis, breast cancer, and other diseases. Upon examining the molecular mechanisms, we found that Smad4, a common signal transducer in the bone morphogenetic protein (BMP)/transforming growth factor-beta (TGF-beta) signaling pathway, functions as a transcription corepressor for human estrogen receptor alpha (ERalpha). Endogenous ERalpha was co-immunoprecipitated with Smad4, and the interaction was induced by antiestrogen ligands such as tamoxifen, raloxifene, and droloxifen, which was confirmed in chromatin immunoprecipitation assays. Smad4 and ERalpha form a complex when ERalpha binds to the estrogen-responsive element within the estrogen target gene promoter. Importantly, the expression of Smad4 inhibits both antiestrogen-induced luciferase activity and estrogen downstream target gene transcription in breast cancer cells. Mapping of the interaction domains indicates that the activation function 1 (AF1) domain of ERalpha is essential for its interaction with Smad4, while the MH1 domain and linker region of Smad4 are essential for the interaction. Our findings represent a novel mechanism that TGF-beta may regulate cell fate through Smad4-mediated cross-talk with estrogen.
Insights
Smad4 acts as a transcription corepressor for estrogen receptor alpha (ERalpha), inhibiting antiestrogen effects in breast cancer cells. This reveals a novel TGF-beta pathway cross-talk mechanism with estrogen signaling.
Area of Science:
- Molecular Biology
- Endocrinology
- Cancer Research
Background:
- Antiestrogens are crucial therapeutics for osteoporosis and breast cancer.
- Estrogen receptor alpha (ERalpha) signaling is a key target in hormone-dependent diseases.
- Smad4 is a critical signal transducer in the bone morphogenetic protein (BMP)/transforming growth factor-beta (TGF-beta) pathway.
Purpose of the Study:
- To elucidate the molecular mechanisms underlying antiestrogen compound action.
- To investigate the interaction between Smad4 and ERalpha.
- To determine the functional role of Smad4 in ERalpha-mediated transcription.
Main Methods:
- Co-immunoprecipitation assays to detect protein-protein interactions.
- Chromatin immunoprecipitation assays to confirm in vivo binding.
- Luciferase reporter assays to measure transcriptional activity.
- Domain mapping to identify interaction interfaces.
Main Results:
- Smad4 physically interacts with ERalpha, and this interaction is enhanced by antiestrogen ligands (tamoxifen, raloxifene, droloxifen).
- Smad4 acts as a transcription corepressor for ERalpha, inhibiting antiestrogen-induced gene expression in breast cancer cells.
- Specific domains (AF1 of ERalpha, MH1 and linker of Smad4) are crucial for the interaction.
Conclusions:
- Smad4 mediates a novel cross-talk between TGF-beta signaling and estrogen signaling.
- This interaction provides a new molecular mechanism for regulating cell fate in response to antiestrogens.
- Targeting the Smad4-ERalpha interaction could offer new therapeutic strategies for hormone-dependent cancers.